KOSDAQ large cap
HK inno.N
A pharma known for K-CAB, a treatment for gastroesophageal reflux disease. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
195940.KQ Updated Jul 11, 2026 2 AI consumers· 2 recurring
Annual return · 2026-07-10'22-1.8%'23+8.6%'24-15.3%'25+60.1%YTD-27%
Money in ▸·
HK inno.N
▸ Money out·
Financials & Segments
- Segments · Prescription drugs (K-CAB) · HB&B (IV fluids and Condition) · Other
Revenue from
No refined links yet.
Pays to
No refined links yet.